Related Experiment Videos
APL and differentiation therapy--joint international congress
1The Institute of Cancer Research: Royal Cancer Hospital, 123 Old Brompton Road, London, SW7 3RP, UK. arthur@icr.ac.uk
Idrugs : the Investigational Drugs Journal
|June 9, 2005
Summary
This conference highlighted progress in differentiation induction therapy for cancer. Oncogene-targeted drugs like ATRA show promise, especially for acute promyelocytic leukemia (APL) and emerging applications in other cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Series of bi-annual conferences since 1985 focused on differentiation induction in cancer therapy.
- Previous conferences successfully fostered interaction between basic and clinical researchers.
Purpose of the Study:
- To promote interaction between basic and clinical investigators in cancer therapy.
- To discuss the role of differentiation induction and oncogene-targeted therapies in cancer treatment.
Main Methods:
- Discussions on clinical applications of differentiation agents.
- Exploration of molecular pathogeneses of cancers responsive to targeted therapies.
- Review of therapeutic successes of all-trans-retinoic acid (ATRA), arsenic trioxide, and STI-571.
Main Results:
- Therapeutic successes of ATRA, arsenic trioxide, and STI-571 underscore the value of oncogene-targeted therapies.
- Significant portion of the congress focused on clinical use and molecular basis of these effective drugs.
- Emerging data suggests promise for differentiation agents beyond acute promyelocytic leukemia (APL).
Conclusions:
- Interactions between basic and clinical researchers are crucial for rational cancer therapeutic design.
- Differentiation induction therapy, while established in APL, shows potential in other malignancies.
- Oncogene-targeted agents represent a key advancement in combating malignant diseases.